DF Deutsche Forfait AG

  • WKN: A2AA20
  • ISIN: DE000A2AA204
  • Land: Deutschland

Nachricht vom 29.09.2021 | 08:00

DF Deutsche Forfait AG publishes half-year figures 2021

DGAP-News: DF Deutsche Forfait AG / Key word(s): Half Year Report/Half Year Results
29.09.2021 / 08:00
The issuer is solely responsible for the content of this announcement.

Half-year financial statements
DF Deutsche Forfait AG publishes half-year figures 2021

  • DF Group's positive development continues in the first half of 2021
  • Business volume at a stable level
  • Consolidated net income improved in the first half of the year to EUR 1.6 million
  • DF Group confirms growth forecast for the full year 2021

Grünwald, 29 September 2021 - DF Deutsche Forfait AG (ISIN: DE000A2AA204) today published its financial figures for the first half of 2021. On an operating level, DF Group realized a largely stable business volume of EUR 86.2 million in the reporting period (H1 2020: EUR 88.1 million). As a result, the Group realized transaction-related income of EUR 4.3 million (previous year: EUR 4.2 million), which mainly included marketing income of EUR 3,503 thousand (previous year: EUR 3,270 thousand), income from services in connection with the processing of payments of EUR 544 thousand (previous year: EUR 371 thousand), and income from the factoring business of EUR 83 thousand (previous year: EUR 0 thousand).

At EUR 1.6 million, consolidated net income in the first half of 2021 was higher than in the same period of the previous year (EUR 1.2 million). The main reason for the improvement in earnings in the first half of 2021 was a slight increase in gross result with a simultaneous decline in administrative expenses.

Dr. Behrooz Abdolvand, CEO of DF Deutsche Forfait AG: "The successful realignment of the last three years has also paid off in the first half of 2021. Although the travel restrictions in connection with the ongoing Corona pandemic have delayed the development of new markets and the launch of additional products, overall our Group has come through the pandemic well. Our strong market knowledge, the high degree of flexibility as well as our longstanding expertise in trade finance, combined with a proven compliance system, provide us with good opportunities to grow business volumes going forward. "

Provided that the economic and political environment remains stable in the coming months and the tensions between the U.S.A. and Iran do not increase, DF Group expects a slight year-on-year increase in business volume, a moderate growth in gross result and a slightly higher consolidated net income before taxes in the current financial year.

The interim consolidated financial statements for the first half of 2021 of DF Deutsche Forfait AG are available on the company's website at https://www.dfag.de/en/investor-relations/publications/ (German only).

About DF Group

DF Group is a global specialist in foreign trade financing with a focus on the Middle East and Eastern Europe. DF Deutsche Forfait focuses on food, pharmaceutical, healthcare, industrial companies, energy and infrastructure sectors. With its extensive financial experience, its distinctive network and its comprehensive compliance expertise, DF Group offers exporters, importers, industrial companies, banks and financial service providers the right financing solution.

 

Contact:
DF Deutsche Forfait AG
Nördliche Münchner Straße 9c
82031 Grünwald
T +49 89 21551900-0
F +49 89 21551900-9
E investor.relations@dfag.de
http://www.dfag.de


Investor Relations / Press:
Stefanie Eberding
T +49 221 9737661
E investor.relations@dfag.de



29.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021